Although RASAL2 is rarely mutated in breast cancer, its expression is reduced due to promoter methylation in about 50% of luminal B tumors, where it is associated with reduced disease-free survival (DFS) and overall survival (OS) [78]. This evidence concerns the gene RASAL2 and breast carcinoma.